Literature DB >> 31011918

High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene.

Kazuhiko Kurozumi1, Yoshiko Nakano2, Joji Ishida3, Takehiro Tanaka4, Masatomo Doi5, Junko Hirato6, Akihiko Yoshida7, Kana Washio8, Akira Shimada8, Takashi Kohno9, Koichi Ichimura2, Hiroyuki Yanai10, Isao Date3.   

Abstract

Here, we report a highly unusual case of high-grade glioneuronal tumor with a neurotrophic tropomyosin receptor kinase (NTRK) fusion gene. A 13-year-old girl presented with headache and vomiting and MRI detected two cystic lesions bilaterally in the frontal areas with surrounding edema. The left larger tumor was removed by left frontal craniotomy. The tumor was diagnosed as a high-grade glioneuronal tumor, unclassified. Methylation profiling classified it as a diffuse leptomeningeal glioneuronal tumor (DLGNT) with low confidence. This tumor showed genotypes frequently found in DLGNT such as 1p/19q codeletion without IDH mutation and, however, did not have the typical DLGNT clinical and histological features. RNA sequencing identified an ARHGEF2 (encoding Rho/Rac guanine nucleotide exchange factor 2)-NTRK1 fusion gene. The presence of recurrent NTRK fusion in glioneuronal tumors has an important implication in the clinical decision making and opens up a possibility of novel targeted therapy.

Entities:  

Keywords:  1p19qLOH; NTRK1; Pediatric brain tumor; RNA sequencing

Mesh:

Substances:

Year:  2019        PMID: 31011918     DOI: 10.1007/s10014-019-00345-y

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  8 in total

1.  Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion.

Authors:  Kazuhiko Kurozumi; Kentaro Fujii; Kana Washio; Joji Ishida; Yoshihiro Otani; Tamotsu Sudo; Makoto Tahara; Koichi Ichimura; Daisuke Ennishi; Isao Date
Journal:  Neurooncol Adv       Date:  2022-06-13

Review 2.  Emerging glioneuronal and neuronal tumors: case-based review.

Authors:  So Dug Lim; Seong Ik Kim; Jin Woo Park; Jae Kyung Won; Seung-Ki Kim; Ji Hoon Phi; Chun-Kee Chung; Seung-Hong Choi; Hongseok Yun; Sung-Hye Park
Journal:  Brain Tumor Pathol       Date:  2022-01-20       Impact factor: 3.298

3.  Dramatic response of STRN-NTRK-fused malignant glioneuronal tumor to larotrectinib in adult.

Authors:  Julie Boyer; Cristina Birzu; Franck Bielle; Clara Goulas; Julien Savatovsky; Carine Karachi; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 13.029

Review 4.  The oncogenic fusion landscape in pediatric CNS neoplasms.

Authors:  Mieke Roosen; Zelda Odé; Jens Bunt; Marcel Kool
Journal:  Acta Neuropathol       Date:  2022-02-15       Impact factor: 15.887

5.  NTRK3 gene fusion in an adult ganglioglioma: illustrative case.

Authors:  Sebastian Rubino; John Lynes; Paul McBride; Solmaz Sahebjam; Sepideh Mokhtari; Joaquim M Farinhas; Arie Perry; Robert Macaulay; Michael A Vogelbaum
Journal:  J Neurosurg Case Lessons       Date:  2022-01-31

6.  Clinical progression, pathological characteristics, and radiological findings in children with diffuse leptomeningeal glioneuronal tumors: A systematic review.

Authors:  Haoxiang Jiang; Lu Qiu; Juan Song; Dandan Xu; Lei Sun; Yinbo Feng; Jun Zhao; Jun Qian; Zhiwei Yu; Jin Peng
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

7.  Molecular and clinicopathologic features of gliomas harboring NTRK fusions.

Authors:  Matthew Torre; Varshini Vasudevaraja; Jonathan Serrano; Michael DeLorenzo; Seth Malinowski; Anne-Florence Blandin; Melanie Pages; Azra H Ligon; Fei Dong; David M Meredith; MacLean P Nasrallah; Craig Horbinski; Sonika Dahiya; Keith L Ligon; Mariarita Santi; Shakti H Ramkissoon; Mariella G Filbin; Matija Snuderl; Sanda Alexandrescu
Journal:  Acta Neuropathol Commun       Date:  2020-07-14       Impact factor: 7.578

Review 8.  Regulation and functions of the RhoA regulatory guanine nucleotide exchange factor GEF-H1.

Authors:  Emily Joo; Michael F Olson
Journal:  Small GTPases       Date:  2020-10-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.